Cognition Therapeutics to Present Analysis Showing Impact of CT1812 on Pathways Implicated in Dry Age-related Macular Degeneration at ARVO 2023

April 19, 2023

https://www.globenewswire.com/news-release/2023/04/19/2649926/0/en/Cognition-Therapeutics-to-Present-Analysis-Showing-Impact-of-CT1812-on-Pathways-Implicated-in-Dry-Age-related-Macular-Degeneration-at-ARVO-2023.html

NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (NASDAQ:CGTX) will be presenting in vitro results characterizing the role of sigma-2 (σ-2) receptors and effect of CT1812 in cell-based models of dry age-related macular degeneration (AMD). CT1812 is an experimental orally delivered, small molecule drug candidate that binds to σ-2 receptors, which have been shown to regulate key cellular processes involved in age-related degenerative diseases.

Read more at globenewswire.com

Related news for (CGTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.